Cargando…

FKBP4 is a malignant indicator in luminal A subtype of breast cancer

Purpose: FKBP4 is a member of the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking associated with HSP90. However, the relationship between abnormal expression of FKBP4 and clinical outcome in luminal A subtype...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Hanchu, Chen, Zihan, Zheng, Wenwen, Sun, Jing, Fu, Qingshuang, Teng, Rongyue, Chen, Jida, Xie, Shuduo, Wang, Linbo, Yu, Xiao-Fang, Zhou, Jichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052866/
https://www.ncbi.nlm.nih.gov/pubmed/32194784
http://dx.doi.org/10.7150/jca.40982
Descripción
Sumario:Purpose: FKBP4 is a member of the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking associated with HSP90. However, the relationship between abnormal expression of FKBP4 and clinical outcome in luminal A subtype breast cancer (LABC) patients remains to be elucidated. Methods: Oncomine, bc-GenExMiner and HPA database were used for data mining and analyzing FKBP4 and its co-expressed genes. GEPIA database was used for screening co-expressed genes of FKBP4. Results: For the first time, we found that higher FKBP4 expression correlated with LABC patients and worse survival. Moreover, the upregulated co-expressed genes of FKBP4 were assessed to be significantly correlated with worse survival in LABC, and might be involved in the biological role of FKBP4. Conclusion: The expression status of FKBP4 is a significant prognostic indicator and a potential drug target for LABC.